# VAH Versus VA for Salvage Therapy of R/R-AML

> **NCT05457361** · PHASE3 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 162 (estimated)

## Conditions studied

- Venetoclax Combined With Azacitidine Plus Homoharringtonine
- Venetoclax Combined With Azacitidine

## Interventions

- **DRUG:** VEN combined with azacitidine plus homoharringtonine
- **DRUG:** VEN combined with azacitidine

## Key facts

- **NCT ID:** NCT05457361
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2022-07-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05457361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05457361, "VAH Versus VA for Salvage Therapy of R/R-AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05457361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*